HRMY - Harmony Biosciences Holdings logo

Harmony Biosciences Holdings

HRMY
Revenue grew 100% of years5Y
Compare HRMY Hold

Harmony Biosciences develops and commercializes therapies for rare neurological diseases, primarily offering WAKIX for narcolepsy. It has multiple products in clinical trials, targeting conditions like Prader-Willi Syndrome, myotonic dystrophy, and Fragile X Syndrome.

โš•๏ธ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago โ†’$1,024today

Score Overview

1 Year
Score
Net Growth14.23%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth10.53%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score8.6
Net Growth423.95%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth214.27%
Rev TrendEvery year
Revenue Consistencyโ€”
All Time
Score
Net Growth6x
Net Trend83%
Net Income Consistency
Rev Growth6x
Rev TrendEvery year
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Harmony Biosciences Holdings has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 1 year of fundamentals. HRMY does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 39.26โ€”
1 Year2025-09-30
$ 27.5642.45%
5 Years2021-09-30
$ 38.332.43%
All Time2020-08-19
$ 37.016.08%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 959M$ 181M$ 667M
2025$ 868M$ 158M$ 775M
2024$ 714M$ 145M$ 467M
2023$ 582M$ 128M$ 353M
2022$ 437M$ 181M$ 323M
2021$ 305M$ 34M$ 234M
IPO2020$ 159M-$ 36M$ 228M
HRMY - Harmony Biosciences Holdings logo

Harmony Biosciences Holdings fundamental performance

Between 2020 and 2025, revenue grew from $ 159M to $ 868M and net income went from -$ 36M to $ 158M. Revenue increased in every one of those 5 years; net income in 4.

Harmony Biosciences Holdings currently holds a 5-year HDB Score of 8.6 out of 10. How the HDB Score is calculated.

Membership

Explore HRMY with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies